LAT010 / Latticon Antibody Therap - LARVOL DELTA

An open-label, dose-escalation and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of combination therapy with LAT010 plus pembrolizumab in patients with locally advanced or metastatic solid tumors (ChiCTR) - P=N/A | N=27 | Sponsor: Shanxi Bethune Hospital; Shanxi Bethune Hospital

New trial • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR • PD-L1 • ROS1

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) (clinicaltrials.gov) - P1/2 | N=150 | Recruiting | Sponsor: Latticon Antibody Therapeutics, Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor • CD4 • CD8

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) (clinicaltrials.gov) - P1/2 | N=150 | Not yet recruiting | Sponsor: Latticon Antibody Therapeutics, Inc

Metastases • New P1/2 trial • Oncology • Solid Tumor • CD4 • CD8